French Media Stock News

ENXTPA:BVI
ENXTPA:BVIProfessional Services

Assessing Bureau Veritas (ENXTPA:BVI) Valuation After Dividend Increase And Board Refresh

Bureau Veritas (ENXTPA:BVI) shares are in focus after the Combined Shareholders’ Meeting approved a cash dividend of €0.92 per share and confirmed board changes, including the appointment of technology specialist Olivier Sévillia as an independent director. See our latest analysis for Bureau Veritas. At a share price of €27.05, Bureau Veritas has seen a 1-month share price return of 4.04%, while the 1-year total shareholder return declined 4.49% despite a 26.18% gain over three years. This...
ENXTPA:VIE
ENXTPA:VIEIntegrated Utilities

Is Veolia Environnement (ENXTPA:VIE) Pricing Its Essential Infrastructure Role Fairly After 21% Annual Gain?

Wondering if Veolia Environnement at €35.33 is offering fair value or if the stock is getting ahead of itself? This article walks through what the numbers are really saying. The stock has returned 3.3% over the last week, is roughly flat over the past month with a 0.6% decline, and is up 17.2% year to date and 21.2% over the past year, so recent gains are front of mind for many investors. Recent news flow around Veolia Environnement has focused on its role as a large integrated utilities...
ENXTPA:AMUN
ENXTPA:AMUNCapital Markets

Amundi Reshapes Organisation As Investors Weigh Growth And Execution Risks

Amundi has announced a comprehensive organisational restructuring, introducing new leadership positions and reshaped business divisions. The reorganisation includes oversight structured by region and function, aiming to support the company’s next phase of development. This refresh of Amundi’s operating model is a material shift for stakeholders tracking ENXTPA:AMUN. For investors watching ENXTPA:AMUN, the timing of this organisational reset comes as the stock trades at €87.0, with returns...
ENXTPA:NANO
ENXTPA:NANOBiotechs

Assessing Nanobiotix (ENXTPA:NANO) Valuation After Strong Recent Share Price Momentum

Recent Price Moves and Context for Nanobiotix Without a specific headline event driving trade today, Nanobiotix (ENXTPA:NANO) has still been on many investors’ radars after a mix of short term volatility and stronger recent share performance. See our latest analysis for Nanobiotix. At a share price of €36.64, Nanobiotix has seen a 30 day share price return of 30.30% and a 90 day share price return of 69.24%, while the 1 year total shareholder return is around 10x. This suggests that momentum...
ENXTPA:EIFF
ENXTPA:EIFFOffice REITs

Assessing Société de la Tour Eiffel (ENXTPA:EIFF) Valuation After A Sharp 3 Month Share Price Rebound

Recent price performance and context Société de la Tour Eiffel (ENXTPA:EIFF) has drawn attention after a very strong past 3 months, with the stock showing a return close to 98% alongside year to date and 1 year gains. See our latest analysis for Société de la Tour Eiffel. That sharp 90 day share price return of 98.05%, alongside a 90.63% year to date share price gain, contrasts with a weaker picture over time. The 3 year total shareholder return has declined 47.83% and the 5 year total...
ENXTPA:BNP
ENXTPA:BNPBanks

BNP Paribas’ US Court Appeal Puts Fresh Attention On Valuation And Undervaluation Claims

Why BNP Paribas’ US court appeal matters for stock watchers BNP Paribas (ENXTPA:BNP) is back in the spotlight as it appeals a US jury verdict of about $20.75 million tied to alleged involvement in transactions linked to human rights abuses in Sudan. The case focuses on whether the bank can be held liable for activities connected to a sanctioned regime, and BNP Paribas argues the trial court misapplied Swiss law and restricted key evidence. See our latest analysis for BNP Paribas. Recent...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

A Look At MedinCell (ENXTPA:MEDCL) Valuation After EMA Accepts TEV-749 Marketing Authorization Application

Teva Pharmaceuticals and MedinCell (ENXTPA:MEDCL) have reached a key regulatory checkpoint, with the European Medicines Agency accepting the Marketing Authorization Application for TEV-749, a long acting injectable olanzapine for schizophrenia. See our latest analysis for MedinCell. The EMA update comes after a strong period for the stock, with a 30 day share price return of 15.37% and a 1 year total shareholder return of 59.14%, suggesting momentum is building around MedinCell's pipeline and...
ENXTPA:ACA
ENXTPA:ACABanks

A Look At Crédit Agricole (ENXTPA:ACA) Valuation After Recent Share Price Pullback

Recent Performance Snapshot for Crédit Agricole Crédit Agricole (ENXTPA:ACA) has drawn investor interest after recent trading, with the stock last closing at €17.26. Short term returns are positive, while performance over the past 3 months and year to date is weaker. See our latest analysis for Crédit Agricole. While the current share price of €17.26 reflects a 7 day share price return of 2.6%, the 90 day share price return is down 6.7%, even as the 5 year total shareholder return of 95.6%...
ENXTPA:FR
ENXTPA:FRAuto Components

Assessing Valeo (ENXTPA:FR) Valuation After Dividend Approval And Boardroom Changes

Valeo (ENXTPA:FR) is back in focus after its 2026 Shareholders’ Meeting approved a €0.44 per share dividend and confirmed several boardroom changes, including a new director and the renewal of the chairman. See our latest analysis for Valeo. The confirmed dividend and refreshed board come as Valeo’s share price trades at €12.64, with a 30 day share price return of 18.08% but a 3 year total shareholder return that is down 27.57%. This suggests recent momentum contrasts with weaker longer term...
ENXTPA:UBI
ENXTPA:UBIEntertainment

Assessing Ubisoft Entertainment (ENXTPA:UBI) Valuation After Deep Losses And Guidance For Another Tough Year

Ubisoft Entertainment (ENXTPA:UBI) is back in focus after its full year 2026 results, reporting sales of €1,395.7 million and a significantly larger net loss of €1,475.2 million compared with the previous year. See our latest analysis for Ubisoft Entertainment. The 1 day share price return of 12.95% to €5.284 came after the earnings release and guidance for another tough year. However, the 1 year total shareholder return is down 46.97%, with multi year total returns also deeply negative. This...
ENXTPA:ALRIB
ENXTPA:ALRIBSemiconductor

Three Undiscovered European Gems To Enhance Your Investment Portfolio

As European markets experience a positive upswing, with the STOXX Europe 600 Index climbing 3.00% amid hopes for geopolitical de-escalation, investors are increasingly interested in small-cap stocks that may offer unique opportunities in this dynamic environment. In such conditions, identifying stocks with strong fundamentals and growth potential can be crucial for enhancing an investment portfolio.
ENXTPA:TE
ENXTPA:TEEnergy Services

The Bull Case For Technip Energies (ENXTPA:TE) Could Change Following US SnapLNG EPC Megaproject Win

Technip Energies announced that it has received Full Notice To Proceed for a major Engineering, Procurement, and Construction contract with Commonwealth LNG’s 9.5 Mtpa export project in Cameron Parish, Louisiana, following the project’s Final Investment Decision. The contract, valued above €1.00 billion and involving six identical SnapLNG by T.EN liquefaction trains, further underlines the company’s role in delivering a significant share of global LNG capacity. We’ll now examine how this...
ENXTPA:ALO
ENXTPA:ALOMachinery

Assessing Alstom (ENXTPA:ALO) Valuation After FY 2026 Sales And Earnings Update

Alstom (ENXTPA:ALO) is back in focus after reporting full year results to March 31, 2026, with sales of €19,171 million and net income of €324 million compared with the prior year. See our latest analysis for Alstom. Alstom’s latest earnings and recent board meeting come after a sharp 90 day share price decline of 42.05% and a year to date fall of 34.31%, while the 1 year total shareholder return is down 8.66%. This suggests recent selling pressure contrasts with longer term performance. If...
ENXTPA:BNP
ENXTPA:BNPBanks

Should BNP Paribas’ Sudan Sanctions Appeal Shift How Investors View Legal Risk At (ENXTPA:BNP)?

Earlier in May 2026, BNP Paribas SA asked a U.S. federal appeals court to overturn a roughly US$20.75 million verdict that found the bank liable for supporting Sudan’s former regime, arguing the trial misapplied Swiss law and improperly limited its evidence. This appeal goes beyond a single payout, testing how far courts can extend banks’ responsibility for transactions involving sanctioned regimes and highlighting legal, compliance and reputational pressures on global lenders. We’ll now...
ENXTPA:SESG
ENXTPA:SESGMedia

SES (ENXTPA:SESG) Is Up 18.3% After Share Cancellations And Governance Revamp Plans - What's Changed

SES S.A. recently reported first-quarter 2026 results showing sales of €847 million versus €509 million a year earlier, alongside a net loss of €16 million, and it called an Extraordinary General Meeting to vote on share cancellations and extensive amendments to its articles of association. Beyond the earnings headline, SES is seeking shareholder approval for a sizeable capital reduction through cancellation of nearly 35.93 million repurchased shares and for new governance measures,...
ENXTPA:ABVX
ENXTPA:ABVXBiotechs

ABIVAX (ENXTPA:ABVX) Q1 Loss Of €48.5 Million Tests Bullish Growth Narratives

ABIVAX Société Anonyme (ENXTPA:ABVX) opened Q1 2026 with revenue of €1.3 million and a loss of €48.5 million, equivalent to EPS of €0.61. This sets a clear picture of a business still investing heavily for future potential rather than current profitability. Over recent quarters, the company has reported revenue between €0.6 million and €4.3 million, while quarterly EPS ranged from €0.61 to €2.10 and quarterly net losses moved between €39.4 million and €153.4 million. This gives investors a...
ENXTPA:OR
ENXTPA:ORPersonal Products

A Look At L'Oréal (ENXTPA:OR) Valuation As The 2026 Big Bang Beauty Tech Program Launches

L'Oréal (ENXTPA:OR) has opened the 2026 Big Bang Beauty Tech Innovation Program, focusing on AI powered commerce, creator ecosystems, and sustainability, which has prompted fresh investor attention on how this approach might relate to the stock. See our latest analysis for L'Oréal. Despite the renewed focus on beauty tech and AI, L'Oréal's share price return has been softer recently, with the 30 day share price return down 4.19% and the 90 day share price return down 8.93%. The 5 year total...
ENXTPA:MEDCL
ENXTPA:MEDCLPharmaceuticals

How Investors May Respond To MedinCell (ENXTPA:MEDCL) After EMA Accepts TEV-749 Schizophrenia Filing

Teva Pharmaceuticals International GmbH and MedinCell have announced that the European Medicines Agency has accepted their Marketing Authorization Application for TEV-749, a once-every-four-weeks subcutaneous olanzapine long-acting injectable for adult schizophrenia, supported by Phase 3 SOLARIS efficacy and safety data. The filing showcases MedinCell’s SteadyTeq copolymer delivery technology in a major psychiatric indication, potentially broadening the clinical and commercial reach of its...
ENXTPA:RMS
ENXTPA:RMSLuxury

A Look At Hermès International (ENXTPA:RMS) Valuation After Recent Share Price Weakness

Hermès International stock performance snapshot Hermès International Société en commandite par actions (ENXTPA:RMS) has drawn investor attention after a period of mixed share performance, with the stock down about 2% over the past month and roughly 24% over the past 3 months. See our latest analysis for Hermès International Société en commandite par actions. At a share price of €1,605.0, Hermès International’s recent 1-day and 7-day share price returns sit in contrast to a much weaker 90-day...
ENXTPA:TKO
ENXTPA:TKOCapital Markets

A Look At Tikehau Capital’s Valuation As Mixed Returns Meet An 18.7% Estimated Discount

What recent returns say about Tikehau Capital (ENXTPA:TKO) Tikehau Capital (ENXTPA:TKO) has delivered mixed share price performance, with the stock up 2.5% in the past day, slightly down over the past week and month, but positive over the past 3 months and year to date. See our latest analysis for Tikehau Capital. Putting this in context, the share price has positive momentum year to date, with a 13.29% year to date share price return. However, the 1 year total shareholder return is down...